Roche said on Wednesday it still believed drugs targeting a protein called beta amyloid had potential to help fight Alzheimer’s disease, despite the high-profile failure of such a product from Eli Lilly. As the setback sent shares in Lilly skidding, Roche pointed out there were significant differences between two experimental Alzheimer’s drugs it was developing and the U.S. drugmaker’s failed solanezumab. “We remain confident in our clinical development programs and continue evaluating two late-stage antibodies that target beta amyloid, crenezumab and gantenerumab,” a Roche spokesman said in a statement.
See original here:
Roche confident in Alzheimer’s program, despite Lilly flop